Gynecomastia Clinical Trial
Official title:
Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System
Protocol is intended for the clinical evaluation of fat reduction in male breasts
(pseudogynecomastia) using the ZELTIQ Coolsculpting System. The ZELTIQ Coolsculpting system
has received market clearance from the U.S.FDA for non-invasive fat layer reduction in the
flanks, and is commercially available.
Primary study endpoint is changes in the shape and reduction of the fat in the breast as
established by photographic imaging and ultrasound imaging of the treated area.
Secondary endpoints will provide supportive data to evaluate device performance (subject
satisfaction & fat reduction measured with ultrasound).
Status | Recruiting |
Enrollment | 12 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - INCLUDED: 1. Male subjects > 18 years of age and < 70 years of age. 2. Subject has clearly visible, palpable, excess fatty tissue in their breast area, and minimal fibrous tissue. 3. Subject has not had weight change exceeding 10 pounds in the preceding month. 4. Subject agrees to maintain their weight (i.e., within +/- 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study. 5. Subject has read and signed a written informed consent form. Exclusion Criteria: EXCLUDED: 1. Subject has had a surgical procedure(s) in the area of intended treatment. 2. Subject has had an invasive fat reduction procedure (e.g., liposuction or mesotherapy) in the area of intended treatment. 3. Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment. 4. Subject needs to administer, or has a known history of, subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. 5. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. 6. Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. 7. Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. 8. Subject body mass index (BMI) exceeds 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. 9. Subject is taking or has taken diet pills or diet supplements within the past month. 10. Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation. 11. Subject is unable or unwilling to comply with the study requirements. 12. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 13. Personal history of previous breast malignancy. 14. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject. 15. Subject is taking any medication which could cause abnormal breast enlargement - including but not limited to: digoxin, furosemide, gonadotropins, clomiphene, phenytoin, and exogenous testosterone, ketoconazole, metronidazole, alkylating agents, cisplatin, spironolactone, cimetidine, flutamide, finasteride, etomidate, isonicotinic acid hydrazide, methyldopa, busulfan, tricyclic antidepressants, diazepam, penicillamine, omeprazole, phenothiazines, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors. 16. Recent history (within the past 5 years) of substance abuse (alcohol, marijuana or heroin). 17. Subject has no history of the following medical conditions: Klinefelter syndrome, Congenital anorchia, Testicular trauma, Testicular torsion, Viral orchitis, Kallmann syndrome , Pituitary tumors, Malignancies that increase the serum level of hCG (eg, large cell lung cancer, gastric carcinoma, renal cell carcinoma, hepatoma), Renal failure, Hyperthyroidism, Malnutrition, Androgen insensitivity syndrome, Five-alpha-reductase deficiency syndrome |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Dermatology, Laser & Vein Specialists of the Carolinas | Charlotte | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Dermatology, Laser & Vein Specialists of the Carolinas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | reduction of the fat layer | Visual, photographic and ultrasound measured changes in the shape and reduction of the fat in the male breast. | 8 months | No |
Secondary | visual reduction of the fat layer | Subject satisfaction measured by subject questionnaires. | 8 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05093049 -
Renuvion APR System When Used as an Adjunct Procedure In Gynecomastia Surgery
|
N/A | |
Completed |
NCT03319862 -
Post-massive Weight Loss Chest Contouring: Inferior Pedicle Technique in Pseudo-gynecomastia Correction
|
N/A | |
Withdrawn |
NCT02711605 -
UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)
|
N/A | |
Completed |
NCT00241436 -
Open Label Arimidex in Gynecomastia
|
Phase 2 | |
Completed |
NCT04425447 -
Thoracic Interfascial Plane Block Versus Thoracic Paravertebral Block in Gynecomastia Surgery
|
N/A | |
Completed |
NCT00637182 -
Gynecomastia Extension Study
|
Phase 3 | |
Recruiting |
NCT04836364 -
Skincare Products and Environmental Health
|
||
Active, not recruiting |
NCT04966078 -
Treatment of Mild and Moderate Cases of Gynaecomastia
|
N/A | |
Completed |
NCT04063722 -
Modified Benelli Procedure For Subcutaneous Mastectomy
|
N/A | |
Not yet recruiting |
NCT06070324 -
Effect of Suture Material on Postoperative Nipple Areolar Complex Widening
|
N/A | |
Withdrawn |
NCT04321967 -
Nitropaste in Breast Reduction
|
Phase 3 |